Tweet
Hi ,
With regards to RCH-01: The company has completed its Phase 2 pre-filing meetings with the German Competent Authority responsible for the authorization of cellular therapies (the Paul Ehrlich Institute) and is in the process of completing cell stability studies required for the Investigational Medical Product Dossier. Submission is planned for early 2014 with the initiation of the trial anticipated in the first half of 2014.
Hope that helps.
Thank you
RepliCel Life Sciences Inc.
Gabrielle Whiteley, Executive Assistant
Dir: 604.248. 8730 Email: gw@replicel.com
2020 – 401 West Georgia Street
Vancouver, BC V6B 5A1
With regards to RCH-01: The company has completed its Phase 2 pre-filing meetings with the German Competent Authority responsible for the authorization of cellular therapies (the Paul Ehrlich Institute) and is in the process of completing cell stability studies required for the Investigational Medical Product Dossier. Submission is planned for early 2014 with the initiation of the trial anticipated in the first half of 2014.
Hope that helps.
Thank you
RepliCel Life Sciences Inc.
Gabrielle Whiteley, Executive Assistant
Dir: 604.248. 8730 Email: gw@replicel.com
2020 – 401 West Georgia Street
Vancouver, BC V6B 5A1
